Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment Information - Summary of Segment Information (Detail)

v3.20.4
Segment Information - Summary of Segment Information (Detail)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
segment
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Segment Reporting Information [Line Items]      
Number of operating segments | segment 2    
Revenues [Abstract]      
Total net revenue $ 444,448 $ 408,830 $ 276,741
Cost of Goods and Services Sold [Abstract]      
Cost of revenue 258,555 211,994 149,476
Gross Profit [Abstract]      
Gross Profit 185,893 196,836 127,265
Operating expenses:      
General and administrative 143,794 127,993 84,822
Research and development 8,229 8,487 3,001
Sales and marketing 47,862 47,350 29,402
Total operating expenses 199,885 183,830 117,225
(LOSS) INCOME FROM OPERATIONS (13,992) 13,006 10,040
Interest expense, net 7,019 3,713 6,230
Other (income) expense, net (11,861) 4,630 (14)
Loss on debt extinguishment 1,400 1,018 0
Loss on termination of cash flow hedge 3,506 0 0
(Loss) income before taxes (14,056) 3,645 3,824
Income tax (benefit) expense (18,228) (4,361) 1,184
NET INCOME 4,172 8,006 2,640
Clinical Services      
Revenues [Abstract]      
Total net revenue 382,337 361,161 241,873
Cost of Goods and Services Sold [Abstract]      
Cost of revenue 215,529 185,612 128,297
Gross Profit [Abstract]      
Gross Profit 166,808 175,549 113,576
Pharma Services      
Revenues [Abstract]      
Total net revenue 62,111 47,669 34,868
Cost of Goods and Services Sold [Abstract]      
Cost of revenue 43,026 26,382 21,179
Gross Profit [Abstract]      
Gross Profit $ 19,085 $ 21,287 $ 13,689